MAXALT

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Estonia, Finland, France, Germany, Italy, Japan, Lithuania, Mexico, Netherlands, Poland, Romania, South Africa, Spain, Turkey, UK.

Active ingredients

The drug MAXALT contains one active pharmaceutical ingredient (API):

1	Rizatriptan UNII WR978S7QHH - RIZATRIPTAN BENZOATE
	Rizatriptan binds selectively with high affinity to human 5-HT1B and 5-HT1D receptors. The therapeutic activity of rizatriptan in treating migraine headache may be attributed to its agonist effects at 5-HT1B and 5-HT1D receptors on the extracerebral intracranial blood vessels that are thought to become dilated during an attack and on the trigeminal sensory nerves that innervate them.
	Read more about Rizatriptan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MAXALT Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N02CC04	Rizatriptan	N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists
Discover more medicines within N02CC04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	9313E
BR	Câmara de Regulação do Mercado de Medicamentos	525501401110219
CA	Health Products and Food Branch	02240518, 02240519, 02240521
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00074435, 00074530, 00074547, 01018143, 01018166, 02404262, 02404374, 16835907
EE	Ravimiamet	1032804, 1076981, 1503919, 1503920, 1503931, 1503942, 1503964, 1503975, 1503986, 1503997, 1504000, 1504011, 1504022, 1504033, 1504044, 1504055, 1504066, 1504077, 1504088, 1504099, 1807208, 1853704, 1866584, 1866595
ES	Centro de información online de medicamentos de la AEMPS	034115117, 10-8012, 3400934794407, 62289, 62291
FI	Lääkealan turvallisuus- ja kehittämiskeskus	396051, 397604, 398222, 539452
FR	Base de données publique des médicaments	64983766, 69922564
GB	Medicines & Healthcare Products Regulatory Agency	139294, 144849, 19131, 19154, 19155, 196163, 196962, 199686, 199688, 199691, 204127, 32051, 32053, 373622, 373623, 373642, 373643, 376750, 381485
HR	Agencija za lijekove i medicinske proizvode	HR-H-455098518
IT	Agenzia del Farmaco	034115042, 034115055, 034115105, 034115117
JP	医薬品医療機器総合機構	2160006F1026, 2160006F2022
LT	Valstybinė vaistų kontrolės tarnyba	1003815, 1014092, 1062313, 1062314, 1062315, 1089052, 1089053, 1090880, 1090881
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	024M98
NL	Z-Index G-Standaard, PRK	50504, 50520
PL	Rejestru Produktów Leczniczych	100252922, 100253063, 100253070, 100253152
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68314001, W68314002, W68314003, W68314004, W68314005, W68315001, W68315002, W68315003, W68315004, W68315005, W68316001, W68316002, W68316003, W68316004, W68316005, W68317001, W68317002, W68317003, W68317004, W68317005
TR	İlaç ve Tıbbi Cihaz Kurumu	8683280337275
US	FDA, National Drug Code	0006-0267, 0006-3801
ZA	Health Products Regulatory Authority	32/7.3/0534, 32/7.3/0535, 32/7.3/0536, 32/7.3/0537